Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
FED Balance Sheet Current State - 5th Mar 21
The Global Vaccine Race Against Time and Variants - 5th Mar 21
US Treasury Yields Rally May Trigger A Crazy Ivan Event (Again) In Stock Market - 5th Mar 21
After Gold’s Slide, What Happens to Miners? - 5th Mar 21
Racism Pandemic Why UK Black and Asians NOT Getting Vaccinated - NHS Covid-19 BAME - 5th Mar 21
Get Ready for Inflation Mega-trend to Surge 2021 - 4th Mar 21
Stocks, Gold – Rebound or Dead Cat Bounce? - 4th Mar 21
The Top Technologies That Are Transforming the Casino Industry - 4th Mar 21
How to Get RICH Crypto Mining Bitcoin, Ethereum With NiceHash - 4th Mar 21
Coronavirus Pandemic Vaccines Indicator Current State - 3rd Mar 21
AI Tech Stocks Investing 2021 Buy Ratings, Levels and Valuations Explained - 3rd Mar 21
Stock Market Bull Trend in Jeopardy - 3rd Mar 21
New Global Reserve Currency? - 3rd Mar 21
Gold To Monetary Base Ratio Says No Hyperinflation - 3rd Mar 21
US Fed Grilled about Its Unsound Currency, Digital Currency Schemes - 3rd Mar 21
The Case Against Inflation - 3rd Mar 21
How to Start Crypto Mining Bitcoins, Ethereum with Your Desktop PC, Laptop with NiceHash - 3rd Mar 21
AI Tech Stocks Investing Portfolio Buying Levels and Valuations 2021 Explained - 2nd Mar 21
There’s A “Chip” Shortage: And TSMC Holds All The Cards - 2nd Mar 21
Why now might be a good time to buy gold and gold juniors - 2nd Mar 21
Silver Is Close To Something Big - 2nd Mar 21
Bitcoin: Let's Put 2 Heart-Pounding Price Drops into Perspective - 2nd Mar 21
Gold Stocks Spring Rally 2021 - 2nd Mar 21
US Housing Market Trend Forecast 2021 - 2nd Mar 21
Covid-19 Vaccinations US House Prices Trend Indicator 2021 - 2nd Mar 21
How blockchain technology will change the online casino - 2nd Mar 21
How Much PC RAM Memory is Good in 2021, 16gb, 32gb or 64gb? - 2nd Mar 21
US Housing Market House Prices Momentum Analysis - 26th Feb 21
FOMC Minutes Disappoint Gold Bulls - 26th Feb 21
Kiss of Life for Gold - 26th Feb 21
Congress May Increase The Moral Hazard Building In The Stock Market - 26th Feb 21
The “Oil Of The Future” Is Set To Soar In 2021 - 26th Feb 21
The Everything Stock Market Rally Continues - 25th Feb 21
Vaccine inequality: A new beginning or another missed opportunity? - 25th Feb 21
What's Next Move For Silver, Gold? Follow US Treasuries and Commodities To Find Out - 25th Feb 21
Warren Buffett Buys a Copper Stock! - 25th Feb 21
Work From Home Inflationary US House Prices BOOM! - 25th Feb 21
Man Takes First Steps Towards Colonising Mars - Nasa Perseverance Rover in Jezero Crater - 25th Feb 21
Musk, Bezos And Cook Are Rushing To Lock In New Lithium Supply - 25th Feb 21
US Debt and Yield Curve (Spread between 2 year and 10 year US bonds) - 24th Feb 21
Should You Buy a Landrover Discovery Sport in 2021? - 24th Feb 21
US Housing Market 2021 and the Inflation Mega-trend - QE4EVER! - 24th Feb 21
M&A Most Commonly Used Software - 24th Feb 21
Is More Stock Market Correction Needed? - 24th Feb 21
VUZE XR Camera 180 3D VR Example Footage Video Image quality - 24th Feb 21
How to Protect Your Positions From A Stock Market Sell-Off Using Options - 24th Feb 21
Why Isn’t Retail Demand for Silver Pushing Up Prices? - 24th Feb 21
2 Stocks That Could Win Big In The Trillion Dollar Battery War - 24th Feb 21
US Economic Trends - GDP, Inflation and Unemployment Impact on House Prices 2021 - 23rd Feb 21
Why the Sky Is Not Falling in Precious Metals - 23rd Feb 21
7 Things Every Businessman Should Know - 23rd Feb 21
For Stocks, has the “Rational Bubble” Popped? - 23rd Feb 21
Will Biden Overheat the Economy and Gold? - 23rd Feb 21
Precious Metals Under Seige? - 23rd Feb 21
US House Prices Trend Forecast Review - 23rd Feb 21
Lithium Prices Soar As Tesla, Apple And Google Fight For Supply - 23rd Feb 21
Stock Markets Discounting Post Covid Economic Boom - 22nd Feb 21
Economics Is Why Vaccination Is So Hard - 22nd Feb 21
Pivotal Session In Stocks Bull Bear Battle - 22nd Feb 21
Gold’s Downtrend: Is This Just the Beginning? - 22nd Feb 21
The Most Exciting Commodities Play Of 2021? - 22nd Feb 21
How to Test NEW and Used GPU, and Benchmark to Make sure it is Working Properly - 22nd Feb 21
US House Prices Vaccinations Indicator - 21st Feb 21
S&P 500 Correction – No Need to Hold Onto Your Hat - 21st Feb 21
Gold Setting Up Major Bottom So Could We See A Breakout Rally Begin Soon? - 21st Feb 21
Owning Real Assets Amid Surreal Financial Markets - 21st Feb 21
Great Investment Ideas For 2021 - 21st Feb 21

Market Oracle FREE Newsletter

FIRST ACCESS to Nadeem Walayat’s Analysis and Trend Forecasts

One Way to Make a Fortune Investing in Healthcare

Stock-Markets / Healthcare Sector Apr 28, 2009 - 06:54 PM GMT

By: Q1_Publishing


Best Financial Markets Analysis ArticleAndrew Grove once said, “I'm a great believer in particularly being alert to changes that change something, anything, by an order of magnitude.”

Grove has been widely credited with Intel’s stunning growth over the years. His unwavering focus on “the next big thing” has allowed Intel to stay one step ahead of competitors for decades. In a period of rapid technological advancement between 1978 and 2004, that was no easy feat.

Needless to say, Grove knows a thing or two about change. And I agree with him completely about keeping a close eye on change too. After all, the rewards for catching onto a major sweeping change early on, and investing in it, are tremendous.

The change we’ll look at today is going to be a very big change. When I say big – mean big. We’ll be looking at a change which has the potential to turn the $500 billion pharmaceutical industry completely upside down.

So when we consider one of our mantras here at the Prosperity Dispatch, “the greater the change, the greater the opportunity,” this is going to be an amazing opportunity.

I feel completely comfortable in saying this is the type of change which will mint many new millionaires. Those who take the time to evaluate and anticipate this change will be handsomely rewarded.

The thing is though, I’m afraid a lot of investors are going to miss this change completely. The headlines are only focusing on the first step of this change. And if you focus all your effort here, you’ll miss out on the big prize.

Two Giant Leaps Away

Change doesn’t happen overnight. It’s especially slow in the world of Big Pharma. But we’re seeing the first giant step forward now.

It’s no secret there are a lot of factors which impede innovation in the drug industry. The time and money it takes to develop a new drug. The FDA approval process to prove a drug is safe and effective. The process of analyzing clinical trial results combined with potential market analysis to decide which drugs to take into the final (and most expensive) trial stages takes a lot of time and money too.

There’s a lot that goes into developing a new drug. Lately, Big Pharma has slowed down developing new drugs. Big Pharma’s drug pipelines are getting smaller. In other words, they have very few new drugs in development. To make matters worse, some of their key cash cow drugs are going “off patent” in the next few years.

Big Pharma’s in a bind. Big Pharma’s leading profit sources are going away soon. Meanwhile, they have very few new drugs to replace those. They’re revenues are about to start declining. They’ll be forced to cut back on research and development. So they’ll have fewer new drugs to increase cash flows, which means less to invest in R&D, and on and on. It’s a downward spiral that is tough to change.

And right now we’re seeing the results of this. We covered the situation back in 2008 in Expiring Patents Ignite Biotech Boom. We predicted a merger boom in the pharmaceutical industry. Big Pharma companies would have to merge just to stay alive. Now, we’re watching it all play out.

We’re seeing everything thing from multi-billion dollar mega –mergers to development deals with small biotech outfits. Merck is merging with Schering-Plough. Pfizer is taking over Wyeth. Roche has signed a merger deal with Genentech. Those are just three of the largest deals. There are dozens of other deals being cut with small biotech companies. And there will be many, many more in the months ahead. It’s the only way they can survive.

But this is only the first step in the process of this change. There will be a few profitable opportunities in this stage. You’ll find these mostly in small biotech companies. But the truly big profits will be reaped in the next development because very few people are watching this one yet.

Stepping Over Nickels to Pick Up Dollar Bills

The big mergers make great headlines. And if you’re in the right stock at the right time, you can get a 20% or 30% premium for your shares.

Also, it feels pretty good to own shares in a small biotech company which jumps up 50% or more after it announces a deal with a Big Pharma firm to help fund the development of its drug.

Don’t get me wrong. In a market like this, 20% to 50% gains are nothing to pass up. But those gains are nothing compared to what can be made in the next leg of the sweeping change hitting Big Pharma – personalized medicine.

Personalized medicine is one of the most interesting emerging technologies affecting the healthcare sector. The potential is practically unlimited.

Personalized Medicine 101

A few decades ago personalized medicine was nothing more than a pipe dream. The idea of having specialized drugs for individuals (more likely small groups of the population) seemed impossible.

How would we be able to categorize everyone? How would we be able to tell whether a particular drug or solution would work just for them? How would we be able to predict which side effects folks in each group would suffer from?

There were just too many questions and not nearly enough answers.

That all changed in 1990. The answers to all those questions were on the way once the U.S. Human Genome Project (HGP) kicked off. The HGP set out to map the entire genome. It was completed in 2003.

The HGP has unlocked all kinds of doors. One of those doors is personalized medicine.

Personalized medicine is basically the ability of drug and therapy developers to create tailored treatments for you. They base your prescription on your specific genetic code. In essence, it really is that simple (for a bit more detailed explanation – follow this link)

Although it may sound like the system would become even more complicated, there are actually many, many benefits to this.  According to the Personalized Medicine Coalition, there are three key benefits to personalized medicine:

              - Better diagnoses and earlier interventions
              - More efficient drug development
              - More effective therapies

Those benefits alone would go a long way to helping Big Pharma work through their current predicament.

The End of an Era

Although personalized medicine would help Big Pharma in many ways, it will also force these bloated bureaucratic companies to change. That is something large organizations don’t do well at all.

Frankly, I believe personalized medicine will bring an end to the “Blockbuster Drug” era. We will no longer see the days of drugs which sell more than $1 billion a year in annual sales.

Now, there will be some blockbusters. They will be for diseases the world doesn’t know relatively much about (i.e. Alzheimer’s disease). But the era when Big Pharma companies need to successfully create the drugs for the masses is coming to an end.

The era of “mass marketed” drugs is coming to a close. It’s not going to happen overnight, but it’s going to happen. That’s why when the mainstream media blasts Big Pharma companies for being terribly managed and failing to keep their pipelines full of new drugs, there’s one question that’s always in the back of my mind…

Maybe – just maybe – the Big Pharma companies are seeing the wave of personalized medicine coming their way and they’re getting preparing for it.

Remember, ExxonMobil barely upped its capital investment budget during the oil bubble. So it is possible for the most experienced people in an industry to see something most other people don’t.

That may or may not be correct. Regardless of it all though, personalized medicine is coming and for those of us looking into this now and making the right moves, it’s tough to imagine a situation where we’re not well rewarded in the end.

A Bumpy Road Ahead

The road to riches is not without potholes. The growth in personalized medicine will be no different. There will be a lot of bumps along the way. The way everything is shaping up to this point, the payoff should be worth the bumps though. But that doesn’t mean we shouldn’t start looking at them now.

By identifying the bumps now, we’ll be able to anticipate them, judge how the market will react, and always stay one step ahead of the market.

One of the biggest hurdles will be ethics. Now, overall it will be better for everyone. However, there will be a few ethical dilemmas. For instance, if there is a certain personalized therapy responding to white males over 50 – the largest and most affluent part of the population – does that mean it should be developed more aggressively? Or should it be developed at the same rate as treatments for everyone?

I’m not going to weigh in here, just trying to pose the question which will come up.

Another big hurdle will be the regulators and lawmakers. We’ve already seen what they’re willing to do to please constituents in the short-term, so how will they handle continued public backlash against Big Pharma?

While researching the healthcare sector over the past few months, I came across the Al Gore/Michael Moore-esque documentary Big Bucks, Big Pharma. (Remember: if it’s a documentary, the things said in it must be true – the more boring, the truer it is)

In it, Marcia Angell, former editor of the New England Journal of Medicine, says, “What the big drug companies are doing now are concentrating on lifestyle drugs that can be marketed to vast numbers of people and the market can be easily expanded.”

Angell identified drug companies were making drugs for baby boomers (lifestyle drugs which reduced effects of allergies, pain, etc) because they are their largest target market. Somehow she made this seem unethical. But I could see how it would sway a lot of people who aren’t in the “target market.”

So there’s another potential issue: politics and regulation.

Despite all that though, this is just too big to prevent some tough decisions to get in the way. The benefits to the medical community will be great. The benefits to patients will be great. The benefits to investors will be great. It’s a win/win/win type of situation we always look out for at the Prosperity Dispatch.

In the end, global healthcare system will be facing a lot of problems in the years ahead. Personalized medicine is a technological innovation which will help alleviate or solve some of those problems. To turn back to the words of Andrew Grove, “Not all problems have a technological answer, but when they do, that is the more lasting solution.”

Andrew Mickey
Chief Investment Strategist, Q1 Publishing

Q1 Publishing is committed to providing investors with well-researched, level-headed, no-nonsense, analysis and investment advice that will allow you to secure enduring wealth and independence.

© 2009 Copyright Q1 Publishing - All Rights Reserved
Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Q1 Publishing Archive

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules